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OBJECTIVES: To estimate direct medical costs and treat-
ment failure rates associated with use of systemic agents
and phototherapy in moderate to severe psoriasis.
METHODS: Patient-level claims data on use of psoria-
sis-related Health care services were obtained from a large
New England payer. Patients with >1 claim listings a 
ICD-9-CM diagnosis code for psoriasis (696.0; 696.1)
were eligible for inclusion. Eligible patients not receiv-
ing systemic treatments (methotrexate, cyclosporin A,
acitretin) or phototherapy (ultraviolet B with or without
tar or petrolatum; psoralen and ultraviolet A [PUVA])
were excluded. Treatment failure was deﬁned as switch
to nonrotational therapy, augmentation with nontopical
therapies, discontinuation following up-titration, or 
discontinuation following hospitalization for psoriasis.
Medical costs included those related to pharmacy
(excluding OTC medication), institutional (inpatient and
outpatient) care, and professional services. Mean costs
within each service category, as well as 99th percentile
costs, were estimated by treatment. RESULTS: A total of
2073 patients were included in the analysis. Over a 1-year
period, approximately 21.7% of patients experienced
treatment failure, with therapy switches accounting for
most occurrences. Mean time to treatment failure ranged
from 3–6 months. Per-patient annual pharmacy costs
were lowest among methotrexate users (US$257) and
highest among cyclosporin users (US$1992). The 99th
percentile of annual pharmacy and institutional costs
exceeded US$10,000, while that of professional service
costs was approximately US$2,500. CONCLUSIONS:
The high variability of direct medical costs among these
patients reﬂects the heterogeneous and chronic nature of
psoriasis. Overall, use of conventional systemic and light
therapies for treatment of moderate to severe psoriasis
was associated with frequent failure and high medical
costs.
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OBJECTIVES: Examining the economic impact of psori-
asis vulgaris during the course of one year and due to a
current skin deterioration (ﬂare). METHODS: A multi-
center, cross-sectional, retrospective, and prospective
cost-of-illness study. Information such as demographic
characteristics, frequency, and number of consulta-
tions, hospitalizations, rehabilitations, out-of-pocket-
expenditures and absence from work were collected by
semi-standardized patient questionnaires and chart
record reviews (12 months retrospectively; 6 weeks
prospectively). Direct, medical and non-medical, and
indirect costs were considered from several perspectives:
patients’, third party payers’ (TPP), societal. Inclusion cri-
teria: moderate to severe chronic plaque psoriasis, age
(18–65 years), ongoing ﬂare, signed informed consent.
RESULTS: Twelve ofﬁce-based dermatologists and 5 out-
patient departments in dermatology hospitals enrolled
227 patients, 56% with moderate and 44% with severe
course of disease. Eighty-six percent of the patients
responded to the questionnaire. Mean age was 47 years,
55% were male. On average, annually TPP reimbursed
€835 per patient. Main cost drivers were prescribed med-
ication (60%) and hospitalization (22%). Patients spent
€596 p.a. mainly for additional treatments (26%) e.g.
alternative therapy, OTC-medication/skin care (29%).
Indirect costs per patient amounted to €1435 p.a., 92%
related to early retirement/unemployment due to psoria-
sis. Total annual costs per patient were €2866, including
€2658 per patient with moderate and €2852 per patient
with severe course of disease. Due to the current ﬂare
32% of the patients received systemic therapy and 61%
were treated exclusively topically and/or with photother-
apy. Direct medical costs (TPP) due to a current ﬂare
amounted to €195 per patient within 6 weeks; including
€449 per patient treated with systemic drugs and €85
treated locally and/or with phototherapy. CONCLU-
SION: Patients and their families bear a sizeable amount
themselves. Also, the burden for TPP and for society is
noticeable. Costs increased remarkably for patients
receiving systemic therapy.
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OBJECTIVES: To estimate the prevalence and the quality
of life of subjects suffering from inﬂammatory dermatitis
(ID) (psoriasis, eczema, atopic dermatitis and urticaria) in
the French population of adults 18 years of age or older.
METHODS: A population-based survey was conducted
among 10,000 adults through personal face to face inter-
views by using the quota sampling method (applied on
age, sex, economic working class and woman working
status). The screening was made by asking the subjects if
they have suffered from one of the 4 ID in the past 12
months or if they have been treated by at least one inﬂam-
matory dermatitis speciﬁc treatment from a pre-deﬁned
list. Subjects answering positively to one of these ques-
tions was considered as a “ID subject”. The quality of life
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was assessed by using the SF-36 questionnaire among the
ID subjects and a randomly selected control group of sub-
jects not suffering from ID (520 persons). RESULTS: The
population surveyed was representative of the French
population in terms of age, sex, and geographic living
area. Patients suffering from ID were similar to the
control group in terms of age, sex, and geographic living
area. The annual prevalence of ID was estimated: 8.8%,
IC 95% = [7.8%; 9.8%]. The SF-36 score of mental
health was signiﬁcantly lower in the ID population: 45.8
versus 48.0 in the control group (p < 0,001). The SF-36
score of physical health was not signiﬁcantly different.
CONCLUSION: The annual prevalence of inﬂammatory
dermatitis is estimated at 9% in French adult population.
People suffering from inﬂammatory dermatitis have a sig-
niﬁcant impact on the mental health dimension of quality
of life but not on physical dimension.
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OBJECTIVE: A common approach to the problem of
interpreting the clinical implications of quality of life
(QoL) scores is to utilize the concept of minimal impor-
tant difference (MID). MID emphasises both the primacy
of patient preferences and the relation between QoL
scores and treatment change. The study purpose is to
illustrate how discrete choice analysis (DCA) could be
used to estimate the relation between QoL and patient
preferences for treatment change. METHODS: A 28-item
atopic dermatitis (AD) QoL instrument was applied to
102 subjects enrolled in a pivotal trial comparing two
alternative AD treatments. Four QoL assessments were
made over 12 months. Subjects were also asked to indi-
cate the extent to which the disease was under control.
Their responses were dichotomized into a variable, which
indicated whether subjects were inclined to seek treat-
ment change, or not. DCA was used to estimate the rela-
tion between probability of treatment change and QoL
scores. RESULTS: QoL scores were found to be a statis-
tically signiﬁcant predictor of the probability that a
subject would seek a treatment change (p < 0.0001 in
each case). The sign on the QoL coefﬁcient was in line
with prior expectations. For both treatments, the proba-
bility that a subject would seek a treatment change
declined over time (from 0.63 to 0.42 for active treat-
ment; 0.63 to 0.57 for comparator). However, the prob-
ability for the new treatment under investigation was
lower at the end of the trials than for the comparator.
CONCLUSIONS: While our analysis is illustrative and
exploratory, the results suggest that DCA offers a promis-
ing approach to the interpretation of QoL scores. By
modeling the direct relation between QoL scores and a
patient’s desire for treatment change, the approach dis-
penses with the need for anchor measures, the interpre-
tation of which is often unclear.
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OBJECTIVES: The objective of the analysis is to evalu-
ate the willingness to pay for topical psoriasis treatment
in Denmark. METHODS: A stated preference method—
discrete choice experiment (DCE) was applied as a postal
survey to 700 members of the Danish Psoriasis Associa-
tion. The respondents were asked to choose between two
hypothetical treatment options. The treatment options
were described by six attributes: Number of products, fre-
quency of application, visual effects, non-visual effects,
three types of side effects and monthly cost. Through
logistic regression it was possible to extract the willing-
ness-to-pay of each attribute and for speciﬁc marketed
treatment options (deﬁned by these attributes).
RESULTS: The survey had a high response rate (73%, or
N = 510), and showed the highest willingness-to-pay for
avoidance of two named side effects (irritated skin and
thin skin) followed by visual effect of the treatment. After
adjusting results of the logistic regression model for
income, the willingness to pay for the best possible treat-
ment option relative to the worst possible treatment
option was DKK 4443 (=€597) per month. The willing-
ness to pay for for a newly launched topical treatment
option containing calcipotriol and bethamethasone
(Daivobet) would thus be DKK 4043 (=€543) compared
to an estimated monthly treatment cost of DKK 683 
(=€92). Thus, the societal welfare gain of a month of
Daivobet treatment is DKK 3360 (=€452). CONCLU-
SION: The survey showed high willingness to pay among
a group of Danish psoriasis patients, especially for
avoided side effects and effective treatment. For a single
product (calcipotriol/bethamethasone (Daivobet)), the
willingness-to-pay proved more than fourfold as high as
the treatment cost.
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OBJECTIVES: Evaluating quality-of-life (QoL) of atopic
dermatitis patients and parents of children with atopic
dermatitis as well as patients’ preferences during and after
